SCM
ACET icon

Silverarc Capital Management’s Adicet Bio ACET Stock Holding History

Silverarc Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,705
Closed -$779K – 71
2024
Q1 		$779K Buy
+20,705
New +$857K 0.22% 65

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Silverarc Capital Management's ACET Position: Q2 2024 in Review

Silverarc Capital Management sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 20,705 shares — an estimated $779K sold.

Silverarc Capital Management first reported a position in ACET in Q1 2024 and held it in 1 quarter. The position peaked at $779K in Q1 2024. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • Silverarc Capital Management reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 20,705 Adicet Bio shares in Q2 2024, an estimated $779K.
  • Silverarc Capital Management first reported a position in Adicet Bio in Q1 2024 and held it in 1 quarter.
  • Silverarc Capital Management's Adicet Bio position peaked at $779K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.